MARKET

KIN

KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.780
+0.390
+8.88%
After Hours: 4.860 +0.08 +1.67% 16:58 03/05 EST
OPEN
4.420
PREV CLOSE
4.390
HIGH
4.830
LOW
4.297
VOLUME
957.74K
TURNOVER
--
52 WEEK HIGH
9.83
52 WEEK LOW
3.105
MARKET CAP
188.77M
P/E (TTM)
-6.8846
1D
5D
1M
3M
1Y
5Y
Kindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Barclays Global Healthcare Conference on March 10 and the H.C. Wainwright Global Life Sciences Conference on March 9...
PR Newswire · 5d ago
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash...
GlobeNewswire · 02/25 21:01
Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US
Benzinga · 02/25 18:37
8-K: Kindred Biosciences, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 16:08
BRIEF-Kindred Biosciences Announces Submission Of Parvovirus Monoclonal Antibody Data For Prophylactic Indication
reuters.com · 02/25 14:11
Kindred submits efficacy data to support KIND-030 prophylactic indication approval
Kindred Biosciences (KIN) announces that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture ((USDA)) Center for Veterinary Biologics for
Seekingalpha · 02/25 13:22
Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department ...
PR Newswire · 02/25 13:01
Is Kindred Biosciences (NASDAQ:KIN) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 02/25 06:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KIN. Analyze the recent business situations of Kindred Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KIN stock price target is 10.89 with a high estimate of 14.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 28.44M
% Owned: 72.02%
Shares Outstanding: 39.49M
TypeInstitutionsShares
Increased
28
1.21M
New
21
152.96K
Decreased
19
574.54K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
President/Chief Executive Officer/Director
Richard Chin
Chief Financial Officer/Secretary
Wendy Wee
Chief Scientific Officer
Hangjun Zhan
Director
Denise Bevers
Independent Director
Ernie Mario
Director
Lyndon Lien
Director
Nanxi Liu
Independent Director
Joseph McCracken
Independent Director
Herbert Montgomery
Independent Director
Raymond Townsend
Independent Director
Ervin Veszpremi
No Data
About KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Webull offers kinds of Kindred Biosciences Inc stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KIN stock methods without spending real money on the virtual paper trading platform.